All In Biotech

Drug Trial Radar · NCT05483868

A Phase 1, Open-label Trial of Belzupacap Sarotalocan (AU-011) in Bladder Cancer

A Phase 1, Open-label Trial of Belzupacap Sarotalocan (AU-011) to Determine the Feasibility and Safety of Intratumoral Injection With or Without Intramural Injection in Subjects With Bladder Cancer

Last checked: Nov 19, 2026Latest source record: Aug 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

55

Planned (sponsor's estimate)

Start

Sep 26, 2022

Primary completion

Mar 2027

Study completion Mar 2027

Sponsor

Lead sponsor
Aura BiosciencesIndustry
Sponsor type
Industry
First posted
Aug 2, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main objectives of this study are to determine the feasibility and safety of Belzupacap Sarotalocan (AU-011, bel-sar) treatment of bladder cancer utilizing focal injections with or without laser application.

Conditions

  • Non-muscle-invasive Bladder Cancer
  • NMIBC
  • Non-Muscle Invasive Bladder Carcinoma
  • Non-Muscle Invasive Bladder Neoplasms
  • Non-Muscle Invasive Bladder Urothelial Carcinoma
  • Urothelial Carcinoma Bladder

Interventions

  • AU-011Drug

    Administration of AU-011 intratumorally and intramurally

  • AU-011 in Combination with Medical Laser AdminstrationCombination product

    AU-011 Intratumorally and Intramurally

  • AU-011 in Combination with Medical Laser AdministrationCombination product

    AU-011 Intratumorally

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety of AU-011: Incidences of SAEs and DLTsTime frame: up to 12 months

Locations

19 sites in 2 countries. Site status is shown where the registry gives one.

  • Arkansas Urology

    Little Rock, Arkansas

  • Tower Urology

    Los Angeles, California

  • Saint John's Cancer Institute

    Santa Monica, California

  • Colorado Clinical Research

    Lakewood, Colorado

  • Montefiore Medical Center

    The Bronx, New York

  • UPMC Hillman Cancer Center

    Pittsburgh, Pennsylvania

  • Carolina Urologic Research Center

    Myrtle Beach, South Carolina

  • Urology Associates, P.C.

    Nashville, Tennessee

  • Urology Clinics of North Texas

    Dallas, Texas

  • Baylor College of Medicine

    Houston, Texas

  • The University of Texas San Antonio

    San Antonio, Texas

  • Urology San Antonio/USA Clinical Trials

    San Antonio, Texas

  • The Urology Place

    San Antonio, Texas

  • Westmead Private Hospital

    Westmead, New South Wales, Australia

  • Austin Health

    Heidelberg, Victoria, Australia

  • Warringal Private Hospital

    Heidelberg, Victoria, Australia

  • Penninsula Private Hospital

    Langwarrin, Victoria, Australia

  • The Royal Melbourne Hospital

    Parkville, Victoria, Australia

  • Hollywood Private Hospital

    Nedlands, Western Australia, Australia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.